{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:33:31Z","timestamp":1794018811503,"version":"4.8.0"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2025,7]]},"abstract":"ABSTRACT<\/jats:title>\n \n \n \n The Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program tested imipenem\/relebactam (IMR) and comparators against a total of 2,258 non-duplicate clinical isolates of\n Enterobacterales (Klebsiella pneumoniae<\/jats:italic>\n and\n Escherichia coli<\/jats:italic>\n ) collected across six Brazilian cities during 2020\u20132021. Antimicrobial susceptibility was determined by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpreted following Brazilian Committee on Antimicrobial Susceptibility (BrCAST)\/European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints.\n Enterobacterales<\/jats:italic>\n isolates were screened for \u03b2-lactamase genes (\n bla<\/jats:italic>\n ) by sequencing. The most frequent isolates identified among\n Enterobacterales<\/jats:italic>\n were\n E. coli<\/jats:italic>\n (\n n<\/jats:italic>\n = 471; 20.9%) and\n K. pneumoniae<\/jats:italic>\n (\n n<\/jats:italic>\n = 453; 20.1%). Susceptibility testing showed that >99% of\n E. coli<\/jats:italic>\n isolates were susceptible to colistin ([COL],\n n<\/jats:italic>\n = 470; 99.8%), meropenem ([MEM],\n n<\/jats:italic>\n = 468; 99.4%), IMR (\n n<\/jats:italic>\n = 468; 99.4%), and ceftazidime\/avibactam ([CZA],\n n<\/jats:italic>\n = 468; 99.4%), whereas a high proportion of\n E. coli<\/jats:italic>\n multidrug-resistant (MDR) isolates were susceptible to COL (\n n<\/jats:italic>\n = 69; 98.6%), CZA (\n n<\/jats:italic>\n = 67; 95.7%), MEM (\n n<\/jats:italic>\n = 67; 95.7%), IMR (\n n<\/jats:italic>\n = 67; 95.7%), and amikacin ([AMK],\n n<\/jats:italic>\n = 66; 94.3%). Overall,\n K. pneumoniae<\/jats:italic>\n isolates were most susceptible to CZA (\n n<\/jats:italic>\n = 414; 91.4%) and IMR (\n n<\/jats:italic>\n = 411; 90.7%) and over 86.0% of\n K. pneumoniae<\/jats:italic>\n MDR isolates were susceptible to CZA (\n n<\/jats:italic>\n = 268; 87.3%) and IMR (\n n<\/jats:italic>\n = 265; 86.3%). This study reported that IMR was one of the most effective\n in vitro<\/jats:italic>\n \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations tested and demonstrated comparable activity to CZA and higher activity than COL against both the\n Enterobacterales<\/jats:italic>\n species tested.\n <\/jats:p>\n \n IMPORTANCE<\/jats:title>\n As new mechanisms of antibiotic resistance continue to emerge, especially with the rise of carbapenem resistance, this study emphasizes the importance of assessing the current landscape of antimicrobial resistance to identify optimal therapeutic approaches. In this way, the publication of national data is significant for understanding local epidemiology to evaluate new drugs and make the best choice among the antimicrobials available in the hospital environment, both for critically ill patients with resistant bacterial infections.<\/jats:p>\n <\/jats:sec>\n <\/jats:sec>","DOI":"10.1128\/spectrum.02543-24","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T13:02:11Z","timestamp":1749128531000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["In vitro<\/i>\n activity of imipenem\/relebactam and comparators against\n Enterobacterales<\/i>\n isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020\u20132021"],"prefix":"10.1128","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-2381","authenticated-orcid":true,"given":"Amanda Azevedo","family":"Bittencourt","sequence":"first","affiliation":[{"name":"Global Medical & Scientific Affairs (GMSA), MSD Brazil","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8306-7646","authenticated-orcid":false,"given":"Vinicius Lima","family":"Faustino","sequence":"additional","affiliation":[{"name":"Global Medical & Scientific Affairs (GMSA), MSD Brazil","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula de Mendon\u00e7a","family":"Batista","sequence":"additional","affiliation":[{"name":"Global Medical & Scientific Affairs (GMSA), MSD Brazil","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lays Paulino","family":"Leonel","sequence":"additional","affiliation":[{"name":"Real World Evidence, IQVIA Brazil","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Della Negra de","family":"Paula","sequence":"additional","affiliation":[{"name":"Global Medical & Scientific Affairs (GMSA), MSD Brazil","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales Jos\u00e9","family":"Polis","sequence":"additional","affiliation":[{"name":"Global Medical & Scientific Affairs (GMSA), MSD Brazil","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050628"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11111621"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11030421"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00672-19"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02927-22"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02753-15"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.01.005"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9100693"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2020.05.010"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8030122"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01471-8"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S224228"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-023-02864-3"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00256-22"},{"key":"e_1_3_4_17_2","unstructured":"2020. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing: clinical and laboratory standards institute. Available from: https:\/\/www.nih.org.pk\/wp-content\/uploads\/2021\/02\/CLSI-2020.pdf"},{"key":"e_1_3_4_18_2","unstructured":"2024. European committee on antimicrobial susceptibility testing - breakpoint tables for interpretation of MICs and zone diameters. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_14.0_Breakpoint_Tables.pdf"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy345"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa480"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph6111335"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00189-22"},{"key":"e_1_3_4_23_2","first-page":"145","article-title":"Monitoring the antimicrobial susceptibility of gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017)","volume":"32","author":"Cant\u00f3n R","year":"2019","unstructured":"Cant\u00f3n R, Loza E, Aznar J, Castillo FJ, Cercenado E, Fraile-Ribot PA, Gonz\u00e1lez-Romo F, L\u00f3pez-Hontangas JL, Rodr\u00edguez-Lozano J, Su\u00e1rez-Barrenechea AI, Tubau F, D\u00edaz-Rega\u00f1\u00f3n J, L\u00f3pez-Mendoza D, SMART-Spain Working Group. 2019. Monitoring the antimicrobial susceptibility of gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017). Rev Esp Quimioter 32:145\u2013155.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw282"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad086"},{"key":"e_1_3_4_26_2","unstructured":"Clinical and laboratory standards institute. methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: clinical and laboratory standards institute Wayne PA; 2018 [MO7 11th: 106-12]. 2018 Available from: https:\/\/clsi.org\/media\/1928\/m07ed11_sample.pdf"},{"key":"e_1_3_4_27_2","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 29th informational supplement. Available from: https:\/\/clsi.org\/media\/2663\/m100ed29_sample.pdf"},{"key":"e_1_3_4_28_2","unstructured":"Brazilian Committee on Antimicrobial Susceptibility Testing. 2024 Available from: http:\/\/brcast.org.br\/documentos"},{"key":"e_1_3_4_29_2","unstructured":"European Committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters. 2019. Version 8.0. V\u00e4xj\u00f6 Sweden"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2015.05.005"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-021-00476-1"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2209"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_226_18"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9020062"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa504"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.10.028"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1519"},{"key":"e_1_3_4_39_2","unstructured":"European centre for disease prevention and control. Surveillance atlas of infectious diseases. 2022. Available from: https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx?Dataset=27&HealthTopic=4."},{"key":"e_1_3_4_40_2","unstructured":"2012. European centre for disease prevention and control. increase in Escherichia coli isolates carrying blaNDM-5 in the European Union\/European Economic area. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/increase-escherichia-coli-isolates-carrying-blandm-5-european-unioneuropean"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.716"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00314"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.008"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05186-14"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198621"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.001104"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-019-1522-7"},{"key":"e_1_3_4_48_2","unstructured":"Andrea P. 2022. Updating Breakpoints in Antimicrobial Susceptibility Testing. Available from: https:\/\/asm.org\/Articles\/2022\/February\/Updating-Breakpoints-in-Antimicrobial-Susceptibili"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt178"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-15"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02543-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02543-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:03:38Z","timestamp":1751375018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.02543-24"}},"subtitle":[],"editor":[{"given":"Krisztina M.","family":"Papp-Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1128\/spectrum.02543-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.02543-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02543-24"}}